In the course of Coronavirus Disease-19 (COVID-19) uncontrolled inflammation has been related to disease severity and unfavorable outcomes. Here, the investigators study the longitudinal changes of pro- and anti-inflammatory markers in a population of patients undergoing maintenance hemodialysis (HD) affected by COVID-19, evaluating the potential modulating effects of two different dialysis approaches
For this prospective randomized study, the investigators recruit maintenance hemodialysis
patients with confirmed COVID-19 infection. After diagnosis, the patients are randomized to
two different dialysis modalities, expanded HD (HDx), performed by use of a medium cut-off
membrane, and standard treatment based on the use of a protein-leaking dialyzer (PLD).
The investigators collect clinical and laboratory data, including circulating pre and
post-dialysis levels of interleukin-6 (IL-6), interleukin-8 (IL-8), interleukin-10 (IL-10),
soluble TLR4 (sTLR4), and interferon-gamma (IFN-g). Samples are collected at diagnosis (T0),
and one and two weeks after the diagnosis (T7 and T14, respectively). Moreover, lymphocyte
and immune cell profiles are evaluated.
Procedure: Expanded Hemodialysis for Covid19 maintenance hemodialysis patients
After Covid19 diagnosis participants are randomized to receive Expanded Hemodialysis for two weeks
Procedure: Hemodialysis by protein-leaking dialyzer for Covid19 maintenance hemodialysis patients
After Covid19 diagnosis participants are randomized to receive hemodialysis by protein-leaking dialyzer for two weeks
Inclusion Criteria:
- Patients undergoing maintenance hemodialysis
- Confirmed severe acute respiratory syndrome-coronavirus2 infection
Exclusion Criteria:
- Acute kidney injury
Ospedale IRCCS San Martino
Genova, Italy
Policlinico IRCCS Ospedale San Matteo
Pavia, Italy
Francesca Viazzi, MD, Study Director
Unit of Nephrology, Dept Internal Medicine, Univerity of Genova and San Martino Hospital